These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 6883352)

  • 1. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
    Staquet MJ; Byar DP; Green SB; Rozencweig M
    Cancer Treat Rep; 1983 Sep; 67(9):753-65. PubMed ID: 6883351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Models and methods used for the selection of antitumor preparations in the USSR and abroad].
    Sof'ina ZP
    Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening at the National Cancer Institute.
    Goldin A; Venditti JM; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155
    [No Abstract]   [Full Text] [Related]  

  • 6. The discovery and development of new antileukemic drugs.
    Grever M; Malspeis L
    Hematol Oncol Clin North Am; 1993 Feb; 7(1):233-54. PubMed ID: 8449860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 8. [Introduction of new screening system in National Cancer Institute].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1984 May; 11(5):1134-9. PubMed ID: 6539100
    [No Abstract]   [Full Text] [Related]  

  • 9. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI.
    Geran RI; Greenberg NH; Macdonald MM; Abbott BJ
    Natl Cancer Inst Monogr; 1977 Mar; (45):151-3. PubMed ID: 927490
    [No Abstract]   [Full Text] [Related]  

  • 10. The linear array.
    Zubrod CG; Schepartz SA; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):13-4. PubMed ID: 927488
    [No Abstract]   [Full Text] [Related]  

  • 11. Preclinical toxicology protocols of the Laboratory of Toxicology.
    Prieur DJ; Young DM; Davis RD; Cooney DA; Guarino AM
    Natl Cancer Inst Monogr; 1977 Mar; (45):159-77. PubMed ID: 412104
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antitumor drug screening at the National Cancer Institute, U.S.A].
    Tsuruo T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2809-15. PubMed ID: 3310904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
    [No Abstract]   [Full Text] [Related]  

  • 15. Historical background of the National Cancer Institute's drug development thrust.
    Zubrod CG; Schepartz SA; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156
    [No Abstract]   [Full Text] [Related]  

  • 16. The NCI Developmental Therapeutics Program.
    Collins JM
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
    [No Abstract]   [Full Text] [Related]  

  • 17. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
    Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
    [No Abstract]   [Full Text] [Related]  

  • 18. History of the National Cancer Institute and the plant screening program.
    Schepartz SA
    Cancer Treat Rep; 1976 Aug; 60(8):975-7. PubMed ID: 791487
    [No Abstract]   [Full Text] [Related]  

  • 19. [Past and current problems in tumor research].
    von Wasielewski E; Sedlacek HH
    Dtsch Med Wochenschr; 1986 Apr; 111(16):630-7. PubMed ID: 3956405
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening of Philippine medicinal plants for anticancer agents using CCNSC Protocols.
    Masilungan VA; Vadlamudi S; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):135-40. PubMed ID: 5109412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.